Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer.
- The name of the study drug involved in this study is:
A phase 2 study of zafirlukast for the treatment of tumor-marker only relapsed ovarian cancer
- ClinicalTrials.gov Identifier: NCT04339140
- Protocol Number: 19-814
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required